Could ZIOPHARM Oncology, Inc. (ZIOP) Lose Strenght? The Stock Increases A Lot Today

December 7, 2017 - By Winifred Garcia

The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is a huge mover today! The stock increased 8.50% or $0.34 during the last trading session, reaching $4.34. About 2.10 million shares traded or 37.48% up from the average. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since December 7, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.
The move comes after 5 months positive chart setup for the $610.34M company. It was reported on Dec, 7 by Barchart.com. We have $4.51 PT which if reached, will make NASDAQ:ZIOP worth $24.41M more.

Analysts await ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings on February, 15. They expect $-0.13 earnings per share, down 18.18 % or $0.02 from last year’s $-0.11 per share. After $-0.13 actual earnings per share reported by ZIOPHARM Oncology, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. The rating was upgraded by Wells Fargo on Wednesday, August 10 to “Market Perform”. The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) earned “Market Perform” rating by Raymond James on Thursday, June 2. Wells Fargo initiated ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on Friday, December 4 with “Underperform” rating. The firm has “Neutral” rating given on Monday, January 25 by Mizuho. The rating was maintained by Mizuho on Wednesday, May 11 with “Neutral”.

More recent ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news were published by: Fool.com which released: “The case for Celldex Therapeutics, Inc.” on November 30, 2017. Also Globenewswire.com published the news titled: “ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 am ET …” on November 17, 2017. Seekingalpha.com‘s news article titled: “ZIOPHARM tries to break downtrend, shares up 6%” with publication date: November 15, 2017 was also an interesting one.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $610.34 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.